Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to 526.49%.

  • Ocular Therapeutix's EBITDA Margin fell 2304100.0% to 526.49% in Q4 2025 from the same period last year, while for Dec 2025 it was 519.75%, marking a year-over-year decrease of 2501700.0%. This contributed to the annual value of 519.75% for FY2025, which is 2501800.0% down from last year.
  • Latest data reveals that Ocular Therapeutix reported EBITDA Margin of 526.49% as of Q4 2025, which was down 2304100.0% from 472.35% recorded in Q3 2025.
  • Ocular Therapeutix's 5-year EBITDA Margin high stood at 127.41% for Q3 2023, and its period low was 597.47% during Q1 2025.
  • Its 5-year average for EBITDA Margin is 255.5%, with a median of 176.35% in 2022.
  • Its EBITDA Margin has fluctuated over the past 5 years, first skyrocketed by 9671900bps in 2021, then plummeted by -3834600bps in 2025.
  • Over the past 5 years, Ocular Therapeutix's EBITDA Margin (Quarter) stood at 146.64% in 2021, then rose by 6bps to 137.56% in 2022, then rose by 2bps to 135.46% in 2023, then tumbled by -119bps to 296.08% in 2024, then plummeted by -78bps to 526.49% in 2025.
  • Its last three reported values are 526.49% in Q4 2025, 472.35% for Q3 2025, and 502.57% during Q2 2025.